Tłumaczenie nie jest jeszcze gotowe. Wyświetlamy oryginalny artykuł.
Novo Nordisk (NVO) CEO and president Mike Doustdar sits down Yahoo Finance Executive Editor Brian Sozzi to discuss the success that the pharmaceutical giant has seen in launching its Wegovy GLP-1 weight-loss pill. Video Transcript 00:00 Speaker A When you and I initially spoke, I think it was the early onset of the the Wegovy pill beginning to hit the markets. And I remember I asked you about, you know, Goldman Sachs being maybe just a little uh, a little disappointed how it how it started. But like to me, what you reported today, this is a big quarter for the Wegovy pill. I mean, has it met your expectations and would you call this a blockbuster? 00:24 Speaker B It has exceeded our expectations.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.